The chiral P-N* ligands [(S)-2-(dimethylamino)-3-phenylpropyl]diphenylphosphine, (S)-phephos, 1, [(S)-2-)-chiraldphos, 4, reacted with [Ru(η 6 -arene)Cl 2 ] 2 (arene = p-cymene, benzene or hexamethylbenzene), in dichloromethane or tetrahydrofuran solution, affording the corresponding [Ru(η 6 -arene)-(P-N*)Cl 2 ] complexes, 5, in which the P-N* acts as a monodentate P-bonded ligand. In methanol the same reactions easily afforded the corresponding chelate complexes [Ru(η 6 -arene)(P-N*)Cl]Cl. Using ligands 1-3, when the arene is p-cymene, 90 : 10 diastereomeric mixtures of the cationic complexes have been obtained while only one diastereomer was formed in the corresponding reactions when the arene is benzene or hexamethylbenzene. The determination of the absolute configuration of the major products as R Ru ,S C diastereoisomers was made from the crystal structure and CD spectra comparison of the complex (R Ru ,S C )-[Ru(η 6 -p-MeC 6 H 4 Pr i )-(S-phglyphos)Cl]BF 4 . Complexes [Ru(η 6 -arene)(P-N*)Cl]Cl were also obtained by adding small amounts of methanol to solutions of [Ru(η 6 -arene)(P-N*)Cl 2 ] in chloroform. A kinetic study, in CDCl 3 solution containing variable amounts of methanol, on the chelation process in the neutral species [Ru(η 6 -arene)(P-N*)Cl 2 ] showed first-order behaviour of the k obs values with the nucleophile (methanol) concentration. The pseudo-first-order rate constants are ascribed to replacement of Cl Ϫ by a molecule of methanol. A reaction mechanism is proposed.
Cationic rhodium(1) complexes containing the new chiral bidentate P,N ligand 2-[l-(1 S,2S,5R)-(-)menthoxydiphenylphosphinolpyridine are prepared and used successfully in the enantioselective hydroformylation of olefinic substrates, styrene, 2-vinylnaphthalene, methylacrylate and vinylacetate.
The new chiral ligands 2‐butyl‐8‐chloro‐1‐(4,8‐di‐tert‐butyl‐2,10‐dimethoxy‐5,7‐dioxa‐6‐phosphadibenzo[a,c]cyclohepten‐6‐yl)‐1,2‐dihydroquinoline (BIPHENPHOSHQUIN, 3) and 2‐butyl‐8‐chloro‐1‐(3,5‐dioxa‐4‐phosphacyclohepta[2,1‐a;3,4‐a′]dinaphthalen‐4‐yl)‐1,2‐dihydroquinoline (BINAPHOSHQUIN, 4; 4a: SaRC, 4b: SaSC) have been synthesized starting from the rigid backbone of 8‐chloroquinoline. The reactions of 3 and 4 with rhodium(I), palladium(II), and platinum(II) substrates are reported. The reaction of 3 with [Rh(CO)2Cl]2 in a 2:1 molar ratio in hexane afforded a binuclear chloro‐bridged rhodium(III) species by intramolecular oxidative addition of the C–Cl bond of ligand 3 across the rhodium(I) centers. The rhodium(III) complex 5, incorporating the enantiomers SaRC‐3 and RaSC‐3, has been fully characterized by X‐ray diffractometry. Reactions of [Pd(PhCN)2Cl2] with the ligands 3 and 4a in 1:2 molar ratio in toluene afforded the products cis‐[Pd(3)2Cl2] (9) and cis‐[Pd(4a)2Cl2] (10). Similarly, reaction of [Pt(COD)I2] with 4a in a 1:2 molar ratio afforded the complex cis‐[Pt(4a)2I2] (11). An X‐ray analysis has been carried out to obtain information on the effect of the ligand 4a on the overall structure of 11.
The complex
trans-[Ir(CO)Cl(Ph2PPy)2]
(1; Ph2PPy =
2-(diphenylphosphino)pyridine) was
obtained in good yield from the reaction of
[Ir(p-toluidine)(CO)2Cl] with
Ph2PPy. It has a
square-planar geometry, as does the analogous Vaska complex, with two
monodentate Ph2PPy
ligands P-bonded to the iridium(I) center. Compound
1 exhibits a reactivity reminiscent of
Vaska's complex; in fact, it adds SO2, halogens, HCl, and
CH3I. The addition of HCl to 1
initially occurs at the pyridine nitrogen atoms of the pendant
Ph2PPy and subsequently at
the iridium(I) center, affording
[Ir(CO)H(Cl)2(Ph2PPyH)2][Cl]2
(6). The addition of a benzene
solution of [Pd(PhCN)2Cl2] to a solution
of 1 in the same solvent yielded, nearly
quantitatively,
the IrIIPdI complex
[IrPd(CO)Cl3(μ-Ph2PPy)2]
(8). The reaction of 1 with
HgCl2, in benzene,
in a 1:1 molar ratio afforded the binuclear complex
[Ir(CO)Cl2(μ-Ph2PPy)2HgCl]
(9). Using
a 1:2 molar ratio the product
[Ir(CO)Cl2(HgCl2)(μ-Ph2PPy)2HgCl]·2CH2Cl2
(10) was obtained.
Compounds 8 and 10 were also characterized
by a single-crystal X-ray diffraction analysis.
The reaction of 1 with
[Cu(NCCH3)4]BF4
afforded, almost quantitatively, the ionic compound
[Ir(CO)Cl(μ-Ph2PPy)2Cu]BF4
(11) as an orange solid. The compound
[Ir(CO)Cl(μ-Ph2PPy)2Tl]PF6 (12) obtained from the reaction of
1 with TlPF6, shows the Ir−Tl bonding and
is
luminescent in frozen CH2Cl2 solution at
77 K with a lifetime of 5 ns (±10%). As opposed
to analogous compounds, in the bimetallic complexes
8−12 the bridging Ph2PPy
ligands
assume a head-to-head structure. The aim of the work was to obtain
some insight into the
beneficial effect of catalytic precursors containing the pendant
Ph2PPy ligand in the
hydroformylation catalytic cycle. Using complex 1 as a
precatalyst in the hydroformylation
of styrene, at 80 °C and under 80 atm of CO/H2 (1:1)
pressure, the rate of the catalytic
process increases significantly with respect to that observed with
Vaska's complex, making
clear a favorable effect of the pendant Ph2PPy ligand.
However, the chemoselectivity of the
process was low. A scheme of the catalytic cycle is proposed.
The new aspects of the catalytic
cycle are: (i) the protonation under equilibrium conditions of one of
the two pyridine nitrogen
atoms of the pendant Ph2PPy ligands in the reductive
elimination of HCl from the dihydride−iridium(III) species formed by oxidative addition of H2
to 1 and (ii) protonolysis, by the proton
coordinated to the pyridine nitrogen atom, of the acyl or σ-alkyl
groups present in the
intermediates formed in the reaction pathway. Unexpectedly,
11 and 12 exhibit catalytic
activity comparable with that of 1. This occurs because
under the experimental conditions
used the Cu−N or Tl−N bonds are broken, giving 1.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.